Lyophilisation Conference 2019

SMi Group3 - 4 June 2019, London, UK
SMi Group announces the return of the 7th Annual Lyophilisation Conference. Lyophilisation (or freeze drying) remains one of the most exciting and rapidly advancing technologies in the pharmaceutical industry to date. By 2020, the lyophilisation equipment market is projected to exceed 8% CAGR reaching approximately £4.4 billion.

Attend this conference along with key opinion leaders from all areas of pharmaceuticals and biologicals to explore formulation science, materials characterisation, novel and alternative technologies, mathematical modelling and regulatory updates.

How Will You Benefit?

Network and learn from leading professionals such as:

Chairs for 2019

  • Sune Klint Andersen, Principal Spray Drying,Janssen Pharmaceuticals
  • Xiaodong Chen, Senior Research Investigator,Bristol-Myers Squibb

Key Speakers include

  • Paul Matejtschuk, Principal Scientist & Section Head, Standardisation Science, NIBSC
  • Davide Fissore, Associate Professor, Politecnico di Torino
  • Michael Dekner, Head Fill & Finish LCM support, Takeda
  • Richard Denk, Head Sales Containment, Skan AG
  • Mostafa Nakach, Head of Pharmaceutical Engineering Group, Sanofi-Aventis R&D
  • Daryl Williams, Professor of Particle Science and Director of Discovery space, Imperial College London
  • Kevin Ward, Director of R&D, Biopharma technology
  • Paul Barry, Development Scientist, Genzyme Ireland Ltd/Sanofi

2019 Highlights

  • Explore the recent advances in lyophilisation methods and technologies from Biopharma Technology
  • Discuss the novel methods that characterise complex pharmaceutical products to aid formulation design from NIBSC
  • Gain insight into the approaches to avoid cross contamination during lyophilisation from SKAN AG
  • Discover a new approach towards process design through the use of micro freeze dryers by Politecno di Torino
  • Examine the use of model-based approach to lyophilisation cycle design from Takeda

For further information and to register, please visit:
http://www.lyophilisation-europe.com/wpnwe

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Lilly and Lycia Therapeutics enter into strategic …

Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, devel...

SK bioscience and GSK start Phase 3 trial of adjuv…

SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination wit...

Blood vessels produce growth factor that promotes …

Blood vessels supply tumors with nutrients and, on the other hand, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a dista...

No serious health effects linked to mRNA COVID-19 …

Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 v...

New study examines 'Achilles heel' of cancer tumou…

Researchers at the University of British Columbia's faculty of medicine and BC Cancer Research Institute have uncovered a weakness in a key enzyme that solid tumour cance...

AI algorithm solves structural biology challenges

Determining the 3D shapes of biological molecules is one of the hardest problems in modern biology and medical discovery. Companies and research institutions often spend ...

First-in-human clinical trial for a vaccine to tre…

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by resear...

A drug costing less than €2 a day helps in the tre…

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at th...

Rheumatoid arthritis treated with implanted cells …

With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically ...

Sandoz strengthens pipeline by entering into agree…

Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). B...

Pfizer and BioNTech submit a variation to EMA with…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that they submitted a variation to the European Medicines Agency (EMA) requesting to update the Condition...

One in three Americans had COVID-19 by the end of …

A new study published in the journal Nature estimates that 103 million Americans, or 31 percent of the U.S. population, had been infected with SARS-CoV-2 by the end of 20...